Business Context and Reporting Period
This Form 8-K Current Report is filed by 180 Life Sciences Corp. (not Forum Markets Inc.) on December 15, 2022. The filing details the approval and implementation of a reverse stock split to address compliance issues with The NASDAQ Capital Market listing requirements.
Key Financial Metrics
This filing is a corporate action report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only quantitative data provided relates to share counts and voting results:
- Pre-Split Outstanding Shares: Approximately 40.5 million.
- Post-Split Outstanding Shares: Approximately 2.0 million.
- Reverse Stock Split Ratio: 1-for-20.
- Voting Participation: 64.8% of voting shares were present at the Special Meeting.
Material Changes Versus Prior Period
The primary material change is the reduction of outstanding common stock by a factor of 20. This action was taken to increase the per-share trading price to meet the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company had received a deficiency letter on September 30, 2022, regarding non-compliance with this rule. Additionally, the number of shares available for issuance under equity compensation plans and warrants has been proportionately adjusted, and exercise prices have been increased inversely to the split ratio.
Guidance, Outlook, and Risks
Outlook and Management Commentary: Management expects the reverse stock split to result in a closing bid price above the $1.00 requirement, thereby securing continued listing on The NASDAQ Capital Market. The split became effective on December 19, 2022, at 12:01 a.m. Eastern Time.
Risks and Contingencies:
- Listing Compliance: Without the split, the company faced potential delisting if it failed to regain compliance by the March 29, 2023 deadline.
- Fractional Shares: No fractional shares will be issued; instead, they will be rounded up to the nearest whole share. No cash will be paid in lieu of fractional shares.
- Ownership Dilution: While percentage ownership remains virtually unchanged, minor adjustments may occur due to rounding.
Important Facts for Investor Verification
- Verify the new CUSIP number for post-split trading: 68236V203.
- Confirm that the trading symbols ATNF (Common Stock) and ATNFW (Warrants) remain unchanged.
- Check that stock options and warrants have been adjusted with a 1-for-20 reduction in share count and a 20-fold increase in exercise price.
- Note that the company is an emerging growth company.
- Review the definitive proxy statement filed on November 16, 2022, for full details on the amendment to the Certificate of Incorporation.